London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East and have access to Premium Chat. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Can't see that myself but to be honest I'll be thrilled to even get listed again after all this time. Wasn't there once some talk of a London listing once we have got the TSX one sorted? If that ever happens then we should be ok with the ISA hopefully.
Does anyone think we'd will ever be able to get this back into an isa :) ?
The Company will be filing shortly an updated prospectus to reflect recent income and shares received by client companies. This was required as we are applying for a listing on TSX tier two which requires only CAD$700,000 in revenue/cash.
The TSX under their listing policy 2.1 can change this if they desire. Should be noted no advisory services company has qualified for a TSX listing so once again CIC is aiming to be the first.
The TSX placed us as tier 3 which is the highest level and is for Investment company. So its quite interesting we are seen as tier two and also site in the tier 3. The investment comes from us earning client equities. Their 3 requires CAD$2 M in investment which we now have.
So we will file a tier 3 prospectus . We are advanced on the majority of the prospectus reading by regulator and exchange.
How much longer this will take is really up to the readers of the prospectus and the exchange.
On our board is Canadian Securities lawyer David Toyoda whom has been with us since 2003 in other companies. Also on the board is Sandey Wang as CFO also based in Canada and been with us since 2005. So solid Canadian based there.
We are looking a at Fortune 500 ex CFO to join our board as our business clients and standing far out ways Sandey level.
We have added 3 staff in Luxembourg to support the securitisation business and we are the only non bank set up and approved for securitisation services. Since 2015 we have been at it in Luxembourg as it was note that the Luxembourg regulator would remove the need to be regulated securitisation investment for professional investors. That was a game changer and in came into force in Nov 2018. We were totally setup and now this will and is delivery very large client fees.
CIC is also developing Middle East and this will come on line in about 3 years.
CIC is never standing still, we are positioning our selves to be aggressive.
expected of course but excellent election result... unless you are domiciled in Scotland. Eh Stuart? :)
At least widow Kranky only has 5% of the overall vote in the uk. Good luck with independence lovey!
This is an extract of a previous posting, however its difficult to establish exactly how large the companies are:
The client advised that it is one of the USA’s leading surgical technology company’s holding 18 different companies. This was achieved against very strong Competition.
CIC has established a new Holding Company to own each of these entities. This will be both a listing and Luxembourg securitisation agreement. It is a multi-million dollar advisory package
Another extract from a Joe Yangtze post: "TD you are complete and utter ****ing dope. That is a major USA pharmaceutical company, turning over more than $20 billion every year. Do you not think that they don’t have top lawyers, investigators doing DD ON CIC? Do me a favour and stop posting like a child. I will send you Thomas the Tank Engine for Xmas."
Apart from the unacceptable language, can you confirm Mixi how a company incorporated in 2017 is turning over $20bn. You will see that there are two companies one with a capital M and a 'Two' the other without. The former was incorporated in 2017 and Fatboy represents. CICC again?
Also Sandey Wang former Cindrigo CFO is now CIC Capital CFO....hmm.
Inge Leutscher former Cindrigo Independent Director and Chairperson of Audit Committee is now an Independent Director of CIC Capital.
Highly rated by SB... check her out.
vote tomorrow. People have fought and died so we can, so vote whatever your persuasion is. JMHO
" The Securitisation Compartment will allow the offering of notes at low interest of up to €90,000,000 to professional investors (non-retail) with each note being €125,000 based on the independent valuation of InnoMedTech operating subsidiary InnoMed Two’s IP. As a leading provider of securitization advisory services, CIC will receive 4.2% administration fee any notes issued and no commission on capital raised".
So potentially over 5 million euros revenue all together on that deal.
Sorry, missed the full text of last paragraph:-
InnoMed Two provides solutions to address a major health concern, Healthcare-Associated Infections (HAI), specifically Catheter-Associated Urinary Tract Infections (CAUTI), a significant cause of morbidity, mortality, and financial cost to the healthcare system of between $28.4 to $33.8 billion in the United States annually.
InnoMedTech Inc. Corporate Update
WILMINGTON, Del., Dec. 11, 2019 (GLOBE NEWSWIRE) -- InnoMedTech Inc. (“InnoMedTech” or the “Company”), recently incorporated in Delaware, USA as a holding parent company, will acquire approx. 84.23% of InnoMed Two (Mobile, Alabama, USA). It is expected the 15.75% non-dilutable interest to be converted into tradable common shares in the future. InnoMedTech is expected to create numerous additional subsidiary companies to hold specific medical technologies under development.
Regulated Public Listing of the Company
The Company is seeking admission (non-offering prospectus) on a regulated stock exchange as part of the Company’s growth strategy. CIC Capital Ltd. (www.CICCapital.com) (“CIC”) has been appointed to provide advisory services in its application of a regulated listing and various other advisory services.
CIC has also agreed to fund the majority advisory services on at a fixed cash cost of US$128,700 and US$900,000 in common shares. CIC has advised that it will distribute in part common shares as a dividend in Specie to its shareholders thus creating a professional investor shareholder base and trading free float over 25% in InnoMedTech.
Securitisation of Medical Surgical Technologies (“IP”)
InnoMedTech will securitise each subsidiary company intellectual property (“IP”) in Luxembourg starting with InnoMed Two. Luxembourg is considered the leading jurisdiction for domiciling IP, providing both protection and low taxation on divestment of assets. CIC will provide a Luxembourg Securitisation Compartment to hold all the Company’s IP. The Securitisation Compartment will allow the offering of notes at low interest of up to €90,000,000 to professional investors (non-retail) with each note being €125,000 based on the independent valuation of InnoMedTech operating subsidiary InnoMed Two’s IP. As a leading provider of securitization advisory services, CIC will receive 4.2% administration fee any notes issued and no commission on capital raised.
InnoMedTech is a dynamic, collaborative network of medical visionaries working together as medical device innovators. As a team, InnoMedTech represents an unparalleled level of experience and expertise in all aspects required to bring new innovative medical devices from concept to commercialization. InnoMedTech’s vision is to provide a way to identify and create innovative devices that deliver unparalleled care revolutionizing the way medical devices are introduced, as well as putting forth improved patient care.
InnoMed Two provides solutions to address a major health concern, Healthcare-Associated Infections (HAI), specifically Catheter-Associated Urinary Tract Infections (CAUTI), a significant cause of morbidity, mortality, and financial cost to the healthcare system of between $28.4 to $3
The actual news with resignations
Joe, posts crossed. Next question then is why are CICC taking on 'problematic' clients and will this have reputational consequences on CICC? Should CICC's DD process have picked up this risk? Are any other of CICC's clients of similar standing? I am sure that you are up to asking those questions.
Actually Joe, I do not see what you mean. How do you know that (SB) CICC pulled out. Would it change your view if Cindrigo had pulled out. Either way what are the ramifications on CICC.
Further to my previous post, I needed to confirm my facts. CICCapital resigned from Cindrigo at same time as the CFO and Lead Independent Director in relation to money laundering in Ukraine and Vietnam. Just to be clear CICG were not involved with any money-laundering nor were the other 2 gentlemen.
??. But they (C) had the poor connections, if you see what I mean.
seems strange for us to pull out ?!?! as long as CIC Capital did the work and remained professional it would be money in the bank..
SB pulled out, for various reasons.
Weren't we connected to Cindringo ?
Nothing to it. :)
based on earned shares being distributed among shareholders. The service rendered ,among others is listing and fund raising. No listing, no value for Specie. Seems to me quite simple.
I guess providing there is no contractual obligation to the client, shares could be distributed via a private company to share holders brokers... who knows!
Our shares have no valuation as tested by the mkts but we are still shareholders.. effectively of a private company currently.